After the anticipated pullback yesterday, traders are looking for another run up by Adventrx Pharmaceuticals Inc. (Amex:ANX).

The filing is expected to be the first NDA submission for Adventrx, who lists Carl Icahn (one of the world's richest billionaire financier, corporate raider, and private investors) as one of its biggest shareholders.

Navelbine, is approved by the FDA to treat advanced non-small cell lung cancer, and approved in Europe to treat non-small cell lung cancer and advanced or metastatic breast cancer. It sells in excess of $200 million a year world-wide. Adventrx' ANX-530 will attempt to compete for the same indications as Navelbine.

The ANX-530 formulation emulsifies vinorelbine into a homogeneous suspension of nanoparticles that may reduce exposure of the venous endothelium during administration of the drug.

Adventrx has yet another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemo agent, Taxotere.

Shares have been rising steadily during the last 2 weeks in anticipation of that news.

Disclosure: Long ANX

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites